.JPG?ad=18507&adview=true)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Surgery and 2 Microbiology and Molecular Genetics, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ; and 3 Antisense Drug Discovery, Isis Pharmaceuticals, Carlsbad, CA
Requests for Reprints: Beverly E. Barton, Department of Surgery, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, MSB G-519, 185 South Orange Avenue, Newark, NJ 07103. Phone: (973) 972-0662; Fax: (973) 972-6803. E-mail: bartonbe{at}umdnj.edu
Signal transducers and activators of transcription (STAT) were originally discovered as components of cytokine signal transduction pathways. Persistent activation of one STAT, STAT3, is a common feature of prostate cancer. Activated STAT3 was found in pathology specimens obtained from prostatectomy in the cancerous areas but not in the normal margins. Because the activation of STAT3 is mediated by the action of an upstream Janus kinase (JAK) kinase, usually JAK1 or JAK2, the activation step for STAT3 might itself be a target for therapy in prostate cancer. However, the redundancy of upstream kinases may make this strategy unreliable for therapy. To develop molecular targets for prostate cancer treatment, JAK kinase and STAT3 inhibition of two prostate cancer lines were compared. DU145 and NRP-154 cells were treated with JAK kinase inhibitors, analyzed for onset of apoptosis, and measured by annexin V binding and propidium iodide uptake. Activation of caspases in the cells was determined by measuring cleaved caspase-3 following treatment. For determining the effect on mitochondrial membrane depolarization that accompanies apoptosis, the fluorescent dye JC-1 was used. STAT3 was specifically inhibited by transfecting either a dominant-negative (DN) STAT3 plasmid or antisense STAT3 oligonucleotides into the cells. To look for reduction in STAT3 levels within cells, fixed and permeabilized prostate cancer cells were stained with antibody to STAT3. We found that more than one JAK kinase is involved in STAT3 activation in prostate cancer lines. AG490 (JAK2 specific) induced apoptosis in DU145 but not in NRP-154 prostate cancer lines, whereas piceatannol (JAK1 specific) induced apoptosis in NRP-154 but not in DU145 cells. Next, we demonstrated efficacy of specific STAT3 inhibitors in prostate cancer lines. Both induction of apoptosis and reduction in intracellular STAT3 protein were observed following treatment with antisense STAT3 oligonucleotides, while transfection of a DN-STAT3 plasmid into both prostate cancer cell lines resulted in loss of viability and onset of apoptosis. We conclude that STAT3-specific inhibitors, rather than JAK kinase-specific inhibitors, should be more useful therapeutically in treating androgen-resistant prostate cancer and that STAT3 is an appropriate target in the treatment of prostate cancer.
Grant support: Funded in part by an award from the Ruth Estrin Goldberg Memorial Cancer Fund (B. E. Barton).
Received 5/21/03; revised 9/16/03; accepted 10/ 9/03.
This article has been cited by other articles:
|
|
 |
|
  H. D. Lewis, A. Winter, T. F. Murphy, S. Tripathi, V. N. Pandey, and B. E. Barton STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends Mol. Cancer Ther., June 1, 2008; 7(6): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Abdulghani, L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M. P. Lisanti, T. Zellweger, K. Alanen, T. Mirtti, et al. Stat3 Promotes Metastatic Progression of Prostate Cancer Am. J. Pathol., June 1, 2008; 172(6): 1717 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Wu, H. Miao, and S. Khan JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Agarwal, A. Tyagi, M. Kaur, and R. Agarwal Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells Carcinogenesis, July 1, 2007; 28(7): 1463 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bellezza, H. Neuwirt, C. Nemes, I. T. Cavarretta, M. Puhr, H. Steiner, A. Minelli, G. Bartsch, F. Offner, A. Hobisch, et al. Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer Am. J. Pathol., December 1, 2006; 169(6): 2199 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Kim, R. W. Mutter, C. Cao, J. M. Albert, E. T. Shinohara, K. R. Sekhar, and B. Lu Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol. Cancer Ther., November 1, 2006; 5(11): 2659 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rocchi, E. Beraldi, S. Ettinger, L. Fazli, R. L. Vessella, C. Nelson, and M. Gleave Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3-Mediated Suppression of Apoptosis Cancer Res., December 1, 2005; 65(23): 11083 - 11093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gao, L. Zhang, J. Hu, F. Li, Y. Shao, D. Zhao, D. V. Kalvakolanu, D. J. Kopecko, X. Zhao, and D.-Q. Xu Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivo Clin. Cancer Res., September 1, 2005; 11(17): 6333 - 6341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Faffe, L. Flynt, M. Mellema, T. R. Whitehead, K. Bourgeois, R. A. Panettieri Jr., E. S. Silverman, and S. A. Shore Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1{beta} Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1040 - L1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|
|
|
|
|
B. E. Barton, T. F. Murphy, P. Shu, H. F. Huang, M. Meyenhofen, and A. Barton Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines Mol. Cancer Ther., October 1, 2004; 3(10): 1183 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Jing, Y. Li, W. Xiong, W. Sha, L. Jing, and D. J. Tweardy G-Quartet Oligonucleotides: A New Class of Signal Transducer and Activator of Transcription 3 Inhibitors That Suppresses Growth of Prostate and Breast Tumors through Induction of Apoptosis Cancer Res., September 15, 2004; 64(18): 6603 - 6609. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
